16th Annual King & Spalding Medical Device Summit

AdvaMed calls for federal privacy laws that reflect how medical devices use patient data differently from consumer health tools.

AdvaMed President and CEO Scott Whitaker testified before the U.S. Senate Finance Committee, bringing attention to the pressing issue of how tariffs could impact the medtech industry and, most importantly, the patients who depend on it. 

At AdvaMed, we’re proud to be recognized for our work on behalf of the medtech community – and we’re especially grateful when that recognition comes from respected voices like Kwame Ulmer of MedTech Impact Partners and our colleagues at Orthogonal. 

A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.

Washington, D.C.—AdvaMed, the Medtech Association, today released its “AI Policy Roadmap,” a detailed policy outline for Congress and the federal agencies with jurisdiction over medtech to consider in promoting the next era of artificial intelligence-enabled medical and digital health technologies to provide patients and clinicians transformative new tools to aid in diagnosis and treatment. 

Join AdvaMed & Porzio for this comprehensive compliance bootcamp to better understand the current medtech compliance framework.

Akin will provide a CLE program covering the latest legal issues for inbound trade and investment, including the Trump Administration’s approach to trade policy and tariff issues, and strategies medical technology companies can employ to assess and mitigate legal risk. Attendees are eligible to receive 1.0 CLE.